Janus kinase
From Proteopedia
| Line 1: | Line 1: | ||
{{STRUCTURE_3tjc| PDB=3tjc | SIZE=350| SCENE= |right|CAPTION=JAK2 complex with inhibitor thienopyridine [[3tjc]] }} | {{STRUCTURE_3tjc| PDB=3tjc | SIZE=350| SCENE= |right|CAPTION=JAK2 complex with inhibitor thienopyridine [[3tjc]] }} | ||
| + | == Function == | ||
| + | '''Janus kinase''' (JAK) are nonreceptor tyrosine kinases which transduces cytokine-mediated signals via the JAK-STAT pathway. The JAK-STAT pathway transmits signals through the cell membrane to DNA promoters thus causing transcription. The name JAK is derived from Just Another Kinase. JAK proteins contain 2 phosphate-transfer domains, one with kinase activity using a phosphotyrosine (PTyr) and the other a pseudokinase domain which negatively regulates the kinase domain. JAK contains seven Janus homology domains named JH1-7. JAK family members are JAK1, JAK2, JAK3 and TYK2<ref>PMID:9382798</ref>.<br /> '''JAK1''' and TYK2 are involved in signaling by members of type I and type II cytokine receptors.<br /> '''JAK2''' is involved in signaling by members of the interferon receptors (type II cytokines).<br /> '''JAK3''' is predominantly active in immune cells. JAK3 is activated by cytokines whose receptors contain the common γ chain subunit (interleukin 2,4,7,9,15,21).<br /> '''TYK2''' is a component of type I and type III interferon signaling pathways. See [[Tyrosine kinase]]. | ||
| - | + | == Relevance == | |
| + | Jak3 inhibitors are tested in treatment of autoimmune diseases and transplant rejection. | ||
| + | |||
| + | == Disease == | ||
| + | Mutations in Jak2 are associated with chronic myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis<ref>PMID:19393837</ref>. Mutations in Jak3 are associated with immune deficiency. | ||
== 3D Structures of Janus kinase == | == 3D Structures of Janus kinase == | ||
| Line 42: | Line 48: | ||
}} | }} | ||
| + | == References == | ||
| + | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 07:03, 4 April 2016
Contents |
Function
Janus kinase (JAK) are nonreceptor tyrosine kinases which transduces cytokine-mediated signals via the JAK-STAT pathway. The JAK-STAT pathway transmits signals through the cell membrane to DNA promoters thus causing transcription. The name JAK is derived from Just Another Kinase. JAK proteins contain 2 phosphate-transfer domains, one with kinase activity using a phosphotyrosine (PTyr) and the other a pseudokinase domain which negatively regulates the kinase domain. JAK contains seven Janus homology domains named JH1-7. JAK family members are JAK1, JAK2, JAK3 and TYK2[1].
JAK1 and TYK2 are involved in signaling by members of type I and type II cytokine receptors.
JAK2 is involved in signaling by members of the interferon receptors (type II cytokines).
JAK3 is predominantly active in immune cells. JAK3 is activated by cytokines whose receptors contain the common γ chain subunit (interleukin 2,4,7,9,15,21).
TYK2 is a component of type I and type III interferon signaling pathways. See Tyrosine kinase.
Relevance
Jak3 inhibitors are tested in treatment of autoimmune diseases and transplant rejection.
Disease
Mutations in Jak2 are associated with chronic myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis[2]. Mutations in Jak3 are associated with immune deficiency.
3D Structures of Janus kinase
Updated on 04-April-2016
References
- ↑ Liu KD, Gaffen SL, Goldsmith MA, Greene WC. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr Biol. 1997 Nov 1;7(11):817-26. PMID:9382798
- ↑ Levine RL. Janus kinase mutations. Semin Oncol. 2009 Apr;36(2 Suppl 1):S6-11. doi: 10.1053/j.seminoncol.2009.02.005. PMID:19393837 doi:http://dx.doi.org/10.1053/j.seminoncol.2009.02.005
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Alexander Berchansky, Joel L. Sussman, Jaime Prilusky
